Literature DB >> 15108017

Quantitative dynamic contrast-enhanced sonography of hepatic tumors.

Detlef Klein1, Manfred Jenett, Heinz-Jochen Gassel, Jörn Sandstede, Dietbert Hahn.   

Abstract

Liver tumors are defined using quantitative dynamic contrast-enhanced ultrasound compared to histological diagnosis, respectively, long-term follow-ups. Forty-two focal liver lesions in 39 patients were examined by contrast harmonic imaging over a period of 2 min after bolus injection of 10-ml galactose-based contrast agent. Vascular enhancement was quantified by using a dedicated software that allowed us to place representative regions of interest (ROI) in the center of the lesion, in the complete lesion, in regular liver parenchyma and in representative liver vessels (artery, vein and portal vein). Peak enhancement was judged to be either in the arterial, portal venous or in the late phase of liver perfusion. The lesion was described as hypovascular, isovascular and hypervascular compared to liver parenchyma. Contrast uptake was described as centrifugal or centripetal and peripheral or homogenous, respectively. Characterization of the lesions was performed unenhanced and after contrast by four independent specialists unaware of histology. Diagnosis of malignancy was evaluated by using a receiver operating characteristic (ROC) analysis, also overall accuracy, average sensitivity, specificity and negative and positive predictive values were calculated. Interobserver agreement was defined by the Kappa statistics. Histologic examination revealed 29 malignant [hepatocellular carcinoma (HCC), n=11; cholangiocellular carcinoma (CCC), n=1; lymphoma, n=1; metastases, n=16)] and 7 benign [hemangioma, n=1; focal nodular hyperplasia (FNH), n=4, adenoma, n=2)] lesions. Six benign lesions (hemangioma n=1; FNH n=5) were proved by long-term follow-up. ROC analysis regarding the diagnosis of malignancy showed values from 0.43 to 0.62 (mean 0.57) before and from 0.70 to 0.80 (mean 0.75) after contrast agent, respectively. The average values for sensitivity, specificity, accuracy and negative and positive predictive values were 66, 26, 62, 45 and 73% unenhanced and 83, 49, 73, 65 and 82% after contrast, respectively. The interobserver agreement was 0.54 and 0.65 for unenhanced and enhanced examinations, respectively. Quantitative dynamic contrast-enhanced sonography improves the diagnosis of malignancy in liver lesions.

Entities:  

Mesh:

Year:  2004        PMID: 15108017     DOI: 10.1007/s00330-004-2299-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  Enhanced color flow images in small hepatocellular carcinoma.

Authors:  H Maruyama; S Matsutani; G Sato; Y Nakano; O Mitsuhashi; M Yoshikawa; M Ebara; H Saisho; M Ohto
Journal:  Abdom Imaging       Date:  2000 Mar-Apr

2.  Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound.

Authors:  L Y Wang; J H Wang; Z Y Lin; M L Yu; S N Lu; W L Chuang; S C Chen; M Y Hseih; J F Tsai; W Y Chang
Journal:  Abdom Imaging       Date:  1997 Mar-Apr

3.  [ROC: a method for comparing the diagnostic performance of imaging procedures].

Authors:  J W Oestmann; M Galanski
Journal:  Rofo       Date:  1989-07

4.  Assessment of vascular patterns of small liver mass lesions: value and limitation of the different Doppler ultrasound modalities.

Authors:  S Gaiani; A Casali; C Serra; F Piscaglia; L Gramantieri; L Volpe; S Siringo; L Bolondi
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  MnDPDP enhanced magnetic resonance imaging of focal liver lesions.

Authors:  L J King; G J C Burkill; E D Scurr; P Vlavianos; I Murray-Lyons; J C Healy
Journal:  Clin Radiol       Date:  2002-12       Impact factor: 2.350

6.  Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases.

Authors:  T Albrecht; C W Hoffmann; S A Schmitz; S Schettler; A Overberg; C T Germer; K J Wolf
Journal:  AJR Am J Roentgenol       Date:  2001-05       Impact factor: 3.959

7.  Developments in echo-enhancing agents.

Authors:  R Schlief
Journal:  Clin Radiol       Date:  1996-02       Impact factor: 2.350

8.  Ultrasound contrast enhancement of tumours.

Authors:  D Cosgrove
Journal:  Clin Radiol       Date:  1996-02       Impact factor: 2.350

9.  Improved imaging of hepatic metastases with delayed pulse inversion harmonic imaging using a contrast agent SH U 508A: preliminary study.

Authors:  T K Kim; B I Choi; H S Hong; B Y Choi; J K Han
Journal:  Ultrasound Med Biol       Date:  2000-11       Impact factor: 2.998

10.  Characterization of liver hemangiomas with pulse inversion harmonic imaging.

Authors:  Emilio Quaia; Michele Bertolotto; Ludovico Dalla Palma
Journal:  Eur Radiol       Date:  2001-11-10       Impact factor: 5.315

View more
  11 in total

1.  Benign focal liver lesions: spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography.

Authors:  Tommaso Vincenzo Bartolotta; Massimo Midiri; Emilio Quaia; Michele Bertolotto; Massimo Galia; Filippo Cademartiri; Roberto Lagalla; Adelfio Elio Cardinale
Journal:  Eur Radiol       Date:  2005-02-15       Impact factor: 5.315

2.  Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrast-enhanced ultrasound.

Authors:  Tommaso Vincenzo Bartolotta; Adele Taibbi; Massimo Galia; Giuseppe Runza; Domenica Matranga; Massimo Midiri; Roberto Lagalla
Journal:  Eur Radiol       Date:  2006-10-03       Impact factor: 5.315

3.  Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US.

Authors:  Tommaso Vincenzo Bartolotta; Massimo Midiri; Emilio Quaia; Michele Bertolotto; Massimo Galia; Filippo Cademartiri; Roberto Lagalla
Journal:  Eur Radiol       Date:  2004-12-21       Impact factor: 5.315

4.  Multiple anechoic hepatic nodules in a patient with malignant lymphoma: report of a case with an emphasis on B-mode sonograms.

Authors:  Yoko Ohyama; Junko Konno; Chioko Yoshida; Naoko Kudoh; Toshiki Sasaki; Takao Hoshino; Hiroyuki Watanabe; Hideaki Ishida; Kayoko Furukawa; Takako Watanabe
Journal:  J Med Ultrason (2001)       Date:  2008-12-16       Impact factor: 1.314

5.  Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound--initial results.

Authors:  M Krix; C Plathow; M Essig; K Herfarth; J Debus; H-U Kauczor; S Delorme
Journal:  Eur Radiol       Date:  2005-02-24       Impact factor: 5.315

Review 6.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

7.  Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model.

Authors:  A Maataoui; J Qian; D Vossoughi; M F Khan; E Oppermann; W O Bechstein; T J Vogl
Journal:  Eur Radiol       Date:  2004-12-04       Impact factor: 5.315

Review 8.  Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis.

Authors:  Shahid M Hussain; Indra C van den Bos; Roy S Dwarkasing; Jan-Willem Kuiper; Jan den Hollander
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 5.315

9.  Characterization of focal liver lesions: comparative study of contrast-enhanced ultrasound versus spiral computed tomography.

Authors:  V Catala; C Nicolau; R Vilana; M Pages; L Bianchi; M Sanchez; C Bru
Journal:  Eur Radiol       Date:  2006-10-27       Impact factor: 5.315

10.  Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound.

Authors:  Li-Da Chen; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Hua Xie; Zuo-Feng Xu; Guang-Jian Liu; Zhu Wang; Man-Xia Lin; Ming-De Lu
Journal:  Eur Radiol       Date:  2009-09-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.